RecruitingNot ApplicableNCT07498959

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease

Sponsor

Sahlgrenska University Hospital

Enrollment

160 participants

Start Date

Mar 19, 2026

Study Type

INTERVENTIONAL

Conditions

Quality of Life Testicular Cancer Seminoma De-escalation RPLND

Summary

The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP) and a procedure called primary RPLND for low-stage metasatatic seminoma for people with de-escalation, quality of life, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.